Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GGH | Q92820 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | ANPEP | P15144 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | FOLH1 | Q04609 | 4/20 | 0.36 |
| ▸ | RIMKLA | Q8IXN7 | 1/20 | 0.36 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7611229 | 0.88 | GGH (0.46) | GGHALDH1A1ANPEPUSP2SMN1; SMN2 | |
| SCHEMBL7608012 | 0.85 | GGH (0.44) | GGHALDH1A1ANPEPUSP2SMN1; SMN2 | |
| SCHEMBL7605295 | 0.79 | GGH (0.50) | GGHALDH1A1SMN1; SMN2FOLH1RIMKLA | |
| SCHEMBL5053128 | 0.79 | ANPEP (0.42) | ALDH1A1ANPEPUSP2SMN1; SMN2HPGD | |
| SCHEMBL5054315 | 0.79 | GGH (0.53) | GGHFOLH1RIMKLANAALAD2LMNA | |
| SCHEMBL5051235 | 0.75 | GRM3 (0.56) | ALDH1A1FOLH1NAALAD2 | |
| SCHEMBL5051305 | 0.75 | HPGD (0.50) | ALDH1A1SMN1; SMN2HPGDALOX12MEN1 | |
| SCHEMBL7611227 | 0.75 | GGH (0.49) | GGHALDH1A1SMN1; SMN2FOLH1RIMKLA | |
| SCHEMBL8065592 | 0.74 | FOLH1 (0.50) | ALDH1A1ANPEPFOLH1NAALAD2 | |
| SCHEMBL5057800 | 0.74 | ALDH1A1 (0.44) | ALDH1A1ANPEPUSP2SMN1; SMN2FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020151503-A1 | Methods of cancer treatment using naaladase inhibitors | SLUSHER BARBARA S (US) | 2002-10-17 | — | — | US | claimed |
| JP-2002514157-A | — | — | 2002-05-14 | — | — | JP | claimed |
| EP-0957924-A4 | CERTAIN PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS | GUILFORD PHARM INC (US) | 2000-04-12 | — | — | EP | claimed |
| EP-0957924-A1 | CERTAIN PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1999-11-24 | — | — | EP | claimed |
| WO-1997048399-A1 | CERTAIN PHOSPHINYL DERIVATIVES USEFUL AS NAALADASE INHIBITORS | GUILFORD PHARMACEUTICALS INC. (US) | 1997-12-24 | — | — | WO | claimed |
| US-6479471-B1 | NOVEL PHOSPHONATE DERIVATIVES, HYDROXYPHOSPHINYL DERIVATIVES, AND PHOSPHORAMIDATE DERIVATIVES THAT INHIBIT N-ACETYLATED .ALPHA.-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME ACTIVITY TO TREAT PROSTATE DISEASES | GUILFORD PHARMACEUTICALS INC. | 2002-11-12 | — | — | US | disclosed |
| US-20020151503-A1 | Methods of cancer treatment using naaladase inhibitors | SLUSHER BARBARA S (US) | 2002-10-17 | — | — | US | disclosed |
| US-6372726-B1 | ADMINISTERING CARBOXYALKYL PHOSPHONATE, PHOSPHORAMIDATE, OR PHOSPHINE OXIDE DERIVATIVE AS ANTITUMOR AGENT TO TREAT CANCER OF PROSTATE GLAND | GUILFORD PHARMACEUTICALS INC. | 2002-04-16 | — | — | US | disclosed |
| US-6025344-A | NOVEL PHOSPHONATE DERIVATIVES, HYDROXYPHOSPHINYL DERIVATIVES, AND PHOSPHORAMIDATE DERIVATIVES THAT INHIBIT N-ACETYLATED .ALPHA.-LINKED ACIDIC DIPEPTIDASE (NAALADASE) ENZYME ACTIVITY, | GUILFORD PHARMACEUTICALS INC. (US) | 2000-02-15 | — | — | US | disclosed |
| US-6011021-A | GLUTAMATE-DERIVED HYDROXYPHOSPHINYL DERIVATIVE. | GUILFORD PHARMACEUTICALS INC. (US) | 2000-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020151503-A1 | Methods of cancer treatment using naaladase inhibitors | NAALAD2, DNPEP, ACP3 | GGH 54/4885ALDH1A1 737/4885ANPEP 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.